Population-level health impact of hypothetical waning 1-dose human papillomavirus vaccination and 2-dose mitigation strategies in a high cervical cancer burden setting
Countries hesitant to adopt a 1-dose HPV vaccination program may have opportunities to leverage the benefits and efficiency of a 1-dose schedule while awaiting longer-term reporting from 1-dose durability studies, including Costa Rica Vaccine Trial.
Authors
- Emily Annika Burger (ORCID: https://orcid.org/0000-0002-6657-5849)
- Jennifer C. Spencer (ORCID: https://orcid.org/0000-0001-9508-1525)
- Allison Portnoy (ORCID: https://orcid.org/0000-0002-8467-1324)
- Élodie Bénard (ORCID: https://orcid.org/0000-0002-7503-0664)
- Jean-François Laprise
- Marc Brisson (ORCID: https://orcid.org/0000-0003-3912-6447)
- Mélanie Drolet
- Stephen Sy
- Mary C. Regan
- Jane J. Kim (ORCID: https://orcid.org/0000-0002-9892-9170)
Institutions
- Boston University (US)
- University of Oslo (NO)
- Université Laval (CA)
- Imperial College London (GB)
- The University of Texas at Austin (US)
Publication Details
- Journal
- JNCI Monographs
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/jncimonographs/lgae039
- Citations
- 4
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.55
Funders
- Bill and Melinda Gates Foundation
- Western Canada Research Grid
- Alliance de recherche numérique du Canada